Follicular Lymphoma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-FL |
|---|---|
| Type | Disease |
| Aliases | FLFollicular lymphoma grade 1-2Follicular lymphoma grade 3AФолікулярна лімфома |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-EHA-WORKUP-2024 SRC-NCCN-BCELL-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9690/3 |
|---|---|
| icd_o_3_topography | [] |
| icd_10 | C82.0 |
| who_classification | Mature B-cell neoplasms — Follicular lymphoma per WHO 5th ed. |
Notes
Risk-stratified by FLIPI / FLIPI2 (informational); 1L decision driven more by GELF criteria (high vs low tumor burden) than FLIPI score. FL grade 3B treated as DLBCL — separate Indication (IND-DLBCL-1L-RCHOP). Transformation to DLBCL (Richter-like, but FL→DLBCL) re-enters DLBCL pathway with worse prognosis baseline.
Used By
Actionability
BMA-BCL2-EXPRESSION-FL- High BCL2 expression universal in FL (driven by t(14;18)). Diagnostic but not therapy-sel...BMA-BCL2-REARRANGEMENT-FL- t(14;18) IGH/BCL2 is the defining genetic lesion of follicular lymphoma (~85%). Drives co...BMA-EZH2-Y641-FL- EZH2 Y641 hotspot activating mutations occur in ~20-25% of follicular lymphoma (and rarel...BMA-MYC-REARRANGEMENT-FL- MYC rearrangement acquired in FL signals transformation to HGBL/DLBCL — change therapy to...
Algorithms
ALGO-FL-1L- ALGO-FL-1LALGO-FL-2L- ALGO-FL-2L
Disease
DIS-DLBCL-NOS- Diffuse Large B-Cell Lymphoma, NOSDIS-HGBL-DH- High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit / triple-hit)DIS-NODAL-MZL- Nodal Marginal Zone Lymphoma
Indication
IND-FL-1L-BR- IND-FL-1L-BRIND-FL-1L-RCHOP-AGGRESSIVE- IND-FL-1L-RCHOP-AGGRESSIVEIND-FL-1L-WATCH- IND-FL-1L-WATCHIND-FL-2L-OBG-BENDA- IND-FL-2L-OBG-BENDAIND-FL-2L-R2- IND-FL-2L-R2IND-FL-3L-AXICEL-CART- IND-FL-3L-AXICEL-CARTIND-FL-3L-MOSUNETUZUMAB- IND-FL-3L-MOSUNETUZUMABIND-FL-3L-TAZEMETOSTAT- IND-FL-3L-TAZEMETOSTATIND-FL-POST-INDUCTION-RITUXIMAB-MAINTENANCE- IND-FL-POST-INDUCTION-RITUXIMAB-MAINTENANCE
Questionnaires
QUEST-FL-1L-STUB- Follicular Lymphoma — first line
Red flag
RF-FL-EZH2-Y641-ACTIONABLE- EZH2 gain-of-function mutation (most commonly Y641 hotspot — Y641F/N/S/H/C + occasional A...RF-FL-FRAILTY-AGE- Frailty profile precluding standard FL combination immunochemo (BR / R-CHOP / G-B / R-Len...RF-FL-HIGH-TUMOR-BURDEN-GELF- Follicular lymphoma meeting GELF criteria for high tumor burden — any of: nodal mass ≥7 c...RF-FL-INFECTION-SCREENING- Active or latent infection requiring resolution / prophylaxis before initiating any anti-...RF-FL-ORGAN-DYSFUNCTION- Baseline organ dysfunction precluding standard FL regimens (BR / R-CHOP / R-Lenalidomide...RF-FL-TRANSFORMATION-SUSPECT- Follicular lymphoma with clinical features concerning for transformation to aggressive ly...RF-FOLLICULAR-TRANSFORMATION- Histologic transformation of follicular lymphoma to DLBCL or high-grade B-cell lymphoma (...RF-GELF-CRITERIA-MET- Follicular lymphoma meeting any GELF criterion — high tumor burden warranting systemic th...RF-GELF-LOW-BURDEN- Follicular lymphoma NOT meeting any GELF criterion — low tumor burden — watch-and-wait ca...
Sources
SRC-AUGMENT-LEONARD-2019- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab i...SRC-ESMO-FL-2024- ESMO Clinical Practice Guideline on Follicular LymphomaSRC-ESMO-LYMPHOMA-2025- Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upSRC-GADOLIN-SEHN-2016- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab...SRC-MORSCHHAUSER-2020-TAZEMETOSTAT-FL- Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label,...SRC-MOZ-UA-LYMPH-2013- Уніфікований клінічний протокол первинної, вторинної (спеціалізованої) медичної допомоги:...